Replimune Group (REPL) Insider Trading & Ownership $9.60 -0.18 (-1.84%) As of 09:54 AM Eastern Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock Replimune Group (NASDAQ:REPL) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage8.80%Number OfInsiders Buying(Last 12 Months)0Number OfInsiders Selling(Last 12 Months)6Amount OfInsider Selling(Last 12 Months)$896.96K Get REPL Insider Trade Alerts Want to know when executives and insiders are buying or selling Replimune Group stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address REPL Insider Buying and Selling by Quarter Replimune Group Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails5/20/2025Andrew SchwendenmanCAOSell3,287$8.05$26,460.35 5/20/2025Christopher SarchiInsiderSell3,749$8.05$30,179.45 5/20/2025Emily Luisa HillCFOSell2,535$8.05$20,406.75 5/20/2025Konstantinos XynosInsiderSell7,952$8.06$64,093.12 5/20/2025Philip Astley-SparkeDirectorSell32,279$8.06$260,168.74 5/20/2025Sushil PatelCEOSell25,105$8.06$202,346.30 12/16/2024Sushil PatelCEOSell10,000$12.42$124,200.00 11/18/2024Konstantinos XynosInsiderSell7,246$10.78$78,111.88 8/16/2024Emily Luisa HillCFOSell8,938$10.18$90,988.84 (Data available from 1/1/2013 forward) REPL Insider Trading Activity - Frequently Asked Questions Who is on Replimune Group's Insider Roster? The list of insiders at Replimune Group includes Andrew Schwendenman, Christopher Sarchi, Colin Love, Emily Luisa Hill, Jean M Franchi, Konstantinos Xynos, Pamela Esposito, Philip Astley-Sparke, Robert Coffin, Sushil Patel, and Tanya Lewis. Learn more on insiders at REPL. What percentage of Replimune Group stock is owned by insiders? 8.80% of Replimune Group stock is owned by insiders. Learn more on REPL's insider holdings. Which Replimune Group insiders have been selling company stock? The following insiders have sold REPL shares in the last 24 months: Andrew Schwendenman ($41,328.41), Christopher Sarchi ($44,529.91), Colin Love ($113,969.05), Emily Luisa Hill ($111,395.59), Konstantinos Xynos ($341,170.46), Pamela Esposito ($938,999.58), Philip Astley-Sparke ($505,562.90), Robert Coffin ($74,172.08), Sushil Patel ($457,201.48), and Tanya Lewis ($309,411.60). How much insider selling is happening at Replimune Group? Insiders have sold a total of 274,220 Replimune Group shares in the last 24 months for a total of $2,937,741.06 sold. Replimune Group Key ExecutivesMr. Philip Astley-Sparke F.S.A. (Age 53)CEO & Director Compensation: $1.07M1 recent tradesDr. Sushil Patel Ph.D. (Age 53)Chief Strategy Officer Compensation: $665.05kDr. Robert Coffin Ph.D. (Age 59)Founder, President, Chief Research & Development Officer and Director Compensation: $785.89kMs. Emily Luisa Hill (Age 44)Chief Financial Officer 1 recent tradesDr. Colin A. Love Ph.D. (Age 66)Chief Operating Officer Compensation: $419.37kMr. Andrew Schwendenman (Age 48)Chief Accounting Officer & Treasurer 1 recent tradesDr. Pamela Esposito Ph.D. (Age 50)Chief Business Officer Compensation: $464.63kMs. Tanya N. Lewis M.S. (Age 53)Chief Development Operations Officer Compensation: $4.7kMr. Christopher Sarchi (Age 56)Chief Commercial Officer 1 recent tradesDr. Konstantinos Xynos M.B.A. (Age 58)M.D., Ph.D., Chief Medical Officer More Insider Trading Tools from MarketBeat Related Companies Viking Therapeutics Insider Trades Scholar Rock Insider Trades Kymera Therapeutics Insider Trades MoonLake Immunotherapeutics Insider Trades Immunovant Insider Trades Lyell Immunopharma Insider Trades Apellis Pharmaceuticals Insider Trades Organon & Co. Insider Trades ImmunityBio Insider Trades Amneal Pharmaceuticals Insider Trades Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles 3 Summer Stocks With Insider Buying and Analyst Support3 Tightly-Held Growth Stocks Set Up for Short SqueezesTankers, Takedowns & Air Taxis: Insiders Are Buying These 3 Names3 Tech Stocks Insiders Are Buying: Speculative Plays for JuneDividend Investors Looking for an Edge? 3 Stocks Insiders Bought This page (NASDAQ:REPL) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredNew Rule Hits in July — The Smart Money Already MovedA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored2025 Market Crash50-Year Legend: Here's The Day Stocks Likely Crash Investing legend finds best cycle indicator during 50-ye...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.